Stealthy NVision Medical has raised $12 million in Series B financing, with funds slated to support product development, clinical studies and regulatory submissions to for its micro-catheter technology.
NVision’s microcatheter technology is designed to allow access to the fallopian tubes without the need for incisions or general anesthesia in hopes of providing “an array of clinical indications previously thought impossible,” the company said.
NVision is focused on using micro-catheter tech for cell collection from the fallopian tube and direct visualization of the fallopian tube, the company said.
“We are pleased with the high level of commitment and enthusiasm from our new and existing investors. nVision’s Series B financing validates the strength of our team’s accomplishments to date. With the Series B financing, we are poised to further develop these technologies, seek additional regulatory clearances, and demonstrate clinical utility,” CEO Surbhi Sarna said in a press release.
The round of financing was led by new investors Arboretum Ventures, and included adding Dr. Tom Shehab to the company’s board of directors.
“We believe nVision is tackling substantial unmet needs within women’s health utilizing a very novel and very promising approach. With this new funding, the company is now well positioned to reach meaningful milestones in the year ahead,” Shehab said in prepared remarks.
The round was joined by all Series A investors, including Catalyst Health Ventures, the company said.
“It’s been a pleasure to support the company from the concept phase to where it is today, having two devices cleared by the FDA and stellar clinical data. We’re very excited about the next steps for the company,” Catalyst Ventures partner Darshana Zaveri said in a prepared statement.
NVision said it won FDA 510(k) clearance for a device that collects cells from the fallopian tube and that it performed the 1st-in-human case for a device which allows for direct visualization of the fallopian tube.
Last week, NVision submitted an SEC filing for $6.5 million in funding. Money in the round came from 17 unnamed sources, and the company is still looking for another $5.5 million before closing, according to an SEC filing.